When can FDA 'refuse to file' NDAs and BLAs? New draft guidance explains
When a new drug application or biologics license application is deemed incomplete by the FDA, the agency can decide not to review the application. So …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
